Skip to Content

Posts tagged with "Patents and IP"

  • Alzheimer's Disease

    Rember for Alzheimer’s: Methylene Blue’s Comeback

    Today we take up the extremely interesting story of Rember, hailed in this week’s press as a potential wonder drug for Alzheimer’s. There are a lot of unusual features to this one. To take the most obvious first, the Phase II data seem to have been impressive. It’s hard to show decent efficacy in an… Read More
  • Drug Development


    I’m going to expand on one of the points brought up yesterday, about the reported drug industry executive who was confident that his company’s Alzheimer’s therapy was ready to go out and make billions of dollars. It was that word “confident” that set me off, I think. Because that’s not a word that you hear… Read More
  • Alzheimer's Disease

    Patents Stopping an Alzheimer’s Wonder Drug?

    A longtime reader sent along a very interesting example that’s being used in a new book. The Gridlock Economy by Columbia economist Michael Heller is getting some good press, including this interview over at the Wall Street Journal>’s Law Blog. Heller’s thesis is: “When too many owners control a single resource, cooperation breaks down, wea… Read More
  • Patents and IP

    Unknown – But You Can Buy It

    I sketched out a rather small molecule the other day, a perfectly reasonable looking thing, which nonetheless had absolutely no references in Chemical Abstracts. (I’d certainly like to be able to put up a drawing of the structure, but it’s something that I have a work-related interest in, so it has to stay under wraps). Read More
  • Business and Markets

    Hearing Footsteps

    The next few years don’t necessarily look good for several large drug companies, just because of the patents that will be expiring. King of them all is Lipitor, of course, the world’s biggest selling drug which will then become the drug industry’s single largest lost revenue stream. But if you dig back through the newspaper… Read More
  • Patents and IP

    Fixing the Patent System?

    For a good long time now, a massive piece of patent legislation has been working its way through Congress. It’s cleared the House and is on its way to the Senate, so the number of twists and turns it can take is still substantial. And there’s no telling if the President will sign it, since… Read More
  • Academia (vs. Industry)

    Ugly, But Useful

      I also mentioned recently that I’d come across a good example of an academic compound with interesting activity but no chance of being a drug. Try this one out, from Organic Letters. Yes, there aren’t many other compounds that do what this one does (inhibit the production of TNF-alpha). And no, it’s not going… Read More
  • Cancer

    Arsenic, Patents, and the World

    As I was mentioning the other day, the latest issue of Nature Medicine has the details on a story that doesn’t, on the face of it, do the industry any credit. About twenty years ago, there were reports out of China that a solublized form of arsenic was very effective in treating acute promyelocytic leukemia… Read More
  • Patents and IP

    Nonsense. On Stilts. Playing a Trumpet.

    A comment in the last post pointed me to an op-ed in today’s New York Times by Suketu Mehta. It’s on India and intellectual property, specifically the idea of patenting yoga techniques. Mehta finds this both laughable and troubling, while noting that most of the applicants are overseas Indians themselves. I’m no yoga expert (maybe… Read More
  • Drug Prices

    Brazil Raises The Pirate Flag

    Back in 2005, the government of Brazil threatened to break the patent on Abbott’s HIV medication Kaletra if the price didn’t come down (see here and here). But after a lot of arm-wrestling, a deal was reached. Now it’s Merck’s turn, with their efavirenz, and this time things went all the way: on Friday, Brazil’s… Read More